ESR1 and neoplasm: To recommend endocrine adjuvant treatment, for hormone receptor-positive patients, the panel was asked to choose between ER threshold level ≥1 vs. ≥10% tested by IHC; the panel was equally split 50/50, while 97% of votes recommended endocrine treatment with any tumor size that include microinvasive disease for patients having luminal A and B like lesions.